{"entity":{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","aka":[],"tldr":"Insight Molecular Diagnostics, the renamed Oncocyte, is a small listed company whose cancer tests read gene activity in tumours to predict who will respond to immunotherapy, alongside a larger business in transplant rejection blood tests.","summary":"Insight Molecular Diagnostics (iMDx), Nasdaq: IMDX, is the former Oncocyte Corporation, which changed its name and moved from Irvine, California to Nashville, Tennessee in June 2025. Its oncology assets include DetermaIO, a 27-gene expression assay of the tumour immune microenvironment intended to predict response to immune checkpoint inhibitors, and DetermaCNI, an in-development blood test measuring genomic copy number instability in circulating tumour DNA to monitor treatment response. The commercial focus has shifted to transplant monitoring with the GraftAssure donor-derived cell-free DNA tests: GraftAssureCore is a laboratory developed test, GraftAssureIQ a research kit and GraftAssureDx is under FDA review for kidney transplant recipients, with a favourable Medicare coverage decision in July 2026. At the end of Q2 2026 the company held $18.7 million in cash.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://imdxinc.com/"},{"label":"Investor relations","url":"https://investors.imdxinc.com/"},{"label":"Q2 2026 results release (Nashville dateline, former name)","url":"https://investors.imdxinc.com/news-releases/2026/08-10-2026-210715920"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["rna-seq","liquid-biopsy","companion-diagnostic"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Oncology is now a minority of the business; transplant testing dominates. Financing amounts for the warrant issuances were not stated in the fetched release so no rounds are recorded. Ticker was OCX before the rename."],"hq":"Nashville, TN","country":"US","companyType":"diagnostics","website":"https://imdxinc.com/","ticker":"IMDX","stage":"public","investors":[],"funding":[]},"route":"/companies/insight-molecular-diagnostics/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}]}}